Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01NJT
|
||||
| Former ID |
DCL000526
|
||||
| Drug Name |
Esreboxetine
|
||||
| Synonyms |
Davedax; Norebox; Prolift; Reboxetine; Solvex; Vestra; Reboxetine [INN]; Reboxetine mesylate; Esreboxetine (USAN/INN); (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; (S,S)-Reboxetine; (S,S)-reboxetine; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Fibromyalgia [ICD9: 729.1; ICD10:M79.7] | Discontinued in Phase 2 | [549540] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H23NO3
|
||||
| Canonical SMILES |
CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3
|
||||
| InChI |
1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1
|
||||
| InChIKey |
CBQGYUDMJHNJBX-OALUTQOASA-N
|
||||
| CAS Number |
CAS 98769-81-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
8189987, 11114256, 14776713, 14801082, 24723456, 43122598, 46504845, 50065436, 50168465, 57315782, 85177295, 85753305, 96026020, 104046804, 104334847, 126650576, 126683279, 134338008, 135253190, 135785545, 137001349, 142214143, 160698609, 160963582, 163213628, 177749680, 178101510, 179338235, 198950509, 198973023, 223519262, 223686602, 226420981, 241124852, 241169861, 246640544
|
||||
| SuperDrug ATC ID |
N06AX18
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Blocker | [549974] | |
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.